Insider Selling: Tango Therapeutics (NASDAQ:TNGX) CFO Sells $126,486.42 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman sold 10,317 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares in the company, valued at $2,259,481.22. The trade was a 5.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $12.51 on Friday. Tango Therapeutics, Inc. has a 1 year low of $1.03 and a 1 year high of $13.46. The business has a 50-day moving average of $10.40 and a two-hundred day moving average of $8.59. The company has a market capitalization of $1.68 billion, a P/E ratio of -13.45 and a beta of 1.75.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.12. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%.The company had revenue of $53.81 million for the quarter, compared to analyst estimates of $41.35 million. On average, equities analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Analyst Ratings Changes

TNGX has been the subject of several analyst reports. B. Riley Financial raised their price objective on Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Wall Street Zen raised Tango Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Stifel Nicolaus assumed coverage on Tango Therapeutics in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a report on Monday, October 27th. Finally, Guggenheim lifted their price target on Tango Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.80.

Institutional Investors Weigh In On Tango Therapeutics

Institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC bought a new position in Tango Therapeutics during the 4th quarter worth $35,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Tango Therapeutics by 148,800.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after acquiring an additional 4,464 shares during the period. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Tango Therapeutics during the 4th quarter worth $40,000. CWM LLC increased its position in shares of Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after purchasing an additional 3,167 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Tango Therapeutics by 52.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the period. 78.99% of the stock is currently owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.